p53 activation enhances the sensitivity of non-small cell lung cancer to the combination of SH003 and docetaxel by inhibiting de novo pyrimidine synthesis.

导出 OA

翻译打印收藏纠错

作者： Yu-Jeong,Choi ^[1] ; Kangwook,Lee ^[2] ; Seo Yeon,Lee ^[3] ; Youngbin,Kwon ^[4] ; Jaehyuk,Woo ^[4] ; Chan-Yong,Jeon ^[5] ; Seong-Gyu,Ko ^[6]

作者单位： Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Korea. ^[1] Department of Food and Biotechnology, Korea University, Sejong, Korea. ^[2] Department of Internal Medicine, Yale University, New Haven, CT, USA. ^[3] Department of Korean Medicine, Graduate School, Kyung Hee University, Seoul, Korea. ^[4] Department of Internal Medicine, College of Korean Medicine, Gachon University, Gyeonggi-Do, Korea. ^[5] Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Korea. epiko@khu.ac.kr. ^[6]

关键词 TP53 Biomarker Combination treatment Docetaxel Non-small cell lung cancer Pyrimidine biosynthesis SH003

DOI 10.1186/s12935-024-03337-x

PMID 38704578

发布时间 2024-05-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交